Literature DB >> 3067337

Clinical tolerance of olsalazine.

G Järnerot1.   

Abstract

Experience of 804 patients treated with olsalazine has shown that this new 5-ASA based drug has a safe clinical profile and good tolerance. The only common side-effect was loose stools or overt diarrhoea, which necessitated withdrawal of the drug in 6.3% of the patients.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3067337     DOI： 10.3109/00365528809101542

Source DB:  PubMed          Journal:  Scand J Gastroenterol Suppl        ISSN： 0085-5928


  5 in total

1.  Optimum dose of olsalazine for maintaining remission in ulcerative colitis.

Authors:  S P Travis; C Tysk; H J de Silva; H Sandberg-Gertzén; D P Jewell; G Järnerot
Journal:  Gut       Date:  1994-09       Impact factor: 23.059

2.  New salicylates as maintenance treatment in ulcerative colitis.

Authors:  G Järnerot
Journal:  Gut       Date:  1994-09       Impact factor: 23.059

Review 3.  Olsalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease.

Authors:  A N Wadworth; A Fitton
Journal:  Drugs       Date:  1991-04       Impact factor: 9.546

4.  Olsalazine in maintenance of clinical remission in patients with ulcerative colitis.

Authors:  J P Wright; E A O'Keefe; L Cuming; K Jaskiewicz
Journal:  Dig Dis Sci       Date:  1993-10       Impact factor: 3.199

Review 5.  Newer 5-aminosalicylic acid based drugs in chronic inflammatory bowel disease.

Authors:  G Järnerot
Journal:  Drugs       Date:  1989-01       Impact factor: 9.546
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.